Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (MRD-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00172068
Recruitment Status : Terminated
First Posted : September 15, 2005
Last Update Posted : December 23, 2009
Information provided by:

Brief Summary:
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases. This open-label study will investigate the safety and efficacy of zoledronic acid in patients with breast cancer and minimal residual disease in the bone marrow.

Condition or disease Intervention/treatment Phase
Primary Breast Cancer Drug: Zoledronic acid + Calcium/Vitamin D Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Tolerability of Intravenous Zometa® (Zoledronic Acid) 4 mg in Primary Breast Cancer Patients With Disseminated Tumor Cells in Bone Marrow. A Prospective, Randomized, Parallel Group, Open-label, Clinical Pilot Study.
Study Start Date : January 2002
Actual Primary Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Treatment Group Drug: Zoledronic acid + Calcium/Vitamin D
Active Comparator: Control Group Drug: Zoledronic acid + Calcium/Vitamin D

Primary Outcome Measures :
  1. Reduction of detected tumor cells in bone marrow [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Tumor cell detection in bone marrow in comparison to the time point of primary surgery (Baseline). [ Time Frame: 24 months ]
  2. Bone metastases-free survival [ Time Frame: 24 months ]
  3. Disease-free survival [ Time Frame: 24 months ]
  4. Bone mineral density [ Time Frame: at 12 and 24 months ]
  5. Number and localization of bone metastases [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients, with primary breast cancer who had undergone complete primary tumor resection and axillary lymph node dissection
  • Evidence of minimal residual disease (disseminated tumor cells in bone marrow)
  • Patients had to receive one of the following adjuvant therapy categories: chemotherapy ± hormonal therapy or hormonal therapy alone

Exclusion Criteria:

  • Inflammatory, metastatic or recurrent breast cancer or a history of breast cancer prior to the currently diagnosed case
  • Neo-adjuvant chemotherapy, neo-adjuvant hormonal therapy, or neo-adjuvant radiotherapy
  • Prior stem cell rescue/bone marrow transplant
  • History of other cancers aside from non-melanomatous skin cancer or carcinoma in situ of the uterine cervix

Additional protocol-defined inclusion / exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00172068

Novartis Invstigative Site
Bielefeld, Germany
Novartis Investigative Site
Hannover, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Tuebingen, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmeceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00172068     History of Changes
Other Study ID Numbers: CZOL446GDE05
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: December 23, 2009
Last Verified: December 2009

Keywords provided by Novartis:
Primary breast cancer
Bone metastases
Minimal residual disease

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm, Residual
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes
Vitamin D
Zoledronic acid
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents